Psoriasis and eczema are both inflammatory skin diseases, and Dermagnostix says its test helps in cases where the clinical picture or the biopsy is ambiguous. Dermagnostix, founded in 2020 as a spin-off of the Hahn-Schickard institute, Helmholtz Munich and the Technical University of Munich, makes PsorX, a test that measures two genes, NOS2 and CCL27, in a skin sample to tell the two apart.
The European Innovation Council granted €2,499,000 towards a €5.17 million project that ran from October 2022 to September 2024. According to the CORDIS report, the LabDisk analyser and its software were "finalized and made ready for series production", the test showed "sensitivity and specificity of more than 95%", and the company closed a €5.4 million Series A. PsorX-LabDisk is now a CE-IVD marked product used by dermatopathology laboratories in Germany and Switzerland.
Company file
- Legal entity
- Dermagnostix GmbH, HRB 728305, Freiburg
- Founded
- December 2020
- CEO
- Natalie Garzorz-Stark, co-founder
- Products
- PsorX-LabDisk test and LabDisk analyser; LymphX in development
- Certification
- EN ISO 13485 since November 2022; PsorX CE-IVD
- Users
- Dermatopathology labs, including DermPath Basel and clinics in Giessen and Erlangen
- EIC project
- DERMAGNOSTIX, 1 Oct 2022 to 30 Sep 2024, closed
Where Dermagnostix Stands Today
The company's partner lab map shows dermatopathology laboratories in Germany and beyond using its system, with "several additional laboratories" being onboarded. In 2025 it bought the DiskReader business, which makes the fluorescence detector used in its analyser, and launched a sub-brand, Lumalytix, according to its about page. It is developing a second test, LymphX, to distinguish a skin lymphoma from psoriasis and eczema. The commercial register shows share capital increases in July 2025 and May 2026.
The Technology: Gene Tests on a Spinning Disk
The test runs an automated RT-qPCR on a standard paraffin-embedded biopsy inside a LabDisk cartridge. The validation of the classifier on tissue, microbiopsies and tape strips was published in the Journal of Investigative Dermatology in 2023. The company says the test "provides added value in 86% of clinically or histologically ambiguous" cases. During the project a prototype batch of 177 cartridges was made for performance evaluation.
"LabDisk analyzer including a connectivity solution as well as front-end and back-end software have been finalized and made ready for series production."
DERMAGNOSTIX project report, CORDIS, 2024What the EIC Project Promised, and What CORDIS Shows
The project promised "pioneering diagnostics in dermatology and cancer". Its milestones were financing, commercial strategy and product development. The report records the Series A, a market strategy for Europe and the US, the finished analyser and the validation work, with analytical validation studies still to be completed for broader commercialisation. A Series B was under discussion for the third quarter of 2024; none has been announced.
- Analyser ready for productionDeliveredPer CORDIS report.
- Validated testDeliveredPublished 2023; CE-IVD.
- FinancingDelivered€5.4M Series A.
- Series BNot announcedPlanned for 2024.
The Money
Dermagnostix extended its seed round by €4.6 million in 2022 and closed a €5.4 million Series A during the EIC project. The register shows further capital increases in 2025 and 2026 whose amounts were not announced. It also received more than €1.2 million of German public funding in 2023 for a diagnostic AI platform, according to North Data. Its revenue and losses are not public.
What Is Not Known
What cannot be checked
How many labs pay for PsorX, how many tests are run, whether health insurers reimburse it, and the company's revenue are not public.
Why Europe Should Care
Dermagnostix turned publicly funded research at German institutes into a certified diagnostic that is in routine lab use. The EIC paid about half the cost of getting its analyser ready for production, and the company has kept raising money since.
What the project promised
Pioneering molecular diagnostics in dermatology and cancer.
What the record shows
A production-ready analyser, a CE-IVD test in German and Swiss labs and new capital, with revenue not public.
The Verdict
A product in use, scale unknown
The EIC project delivered the analyser and helped Dermagnostix bring a certified test into laboratories. How widely it is used, and whether it pays, the public record does not show.
Dermagnostix has not been asked for comment for this article. It is based entirely on company statements, German register data, scientific literature and EU project data, linked throughout.
